Dewpoint Therapeutics
Boston, Massachusetts, United States · Biotechnology, research · 97 employees
Dewpoint Therapeutics is the first company to apply an emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology
Funding history
- Funding Round — $59.1M — Sep 2025
- Funding Round — $150.0M — Feb 2022
- Series series c — $150.0M — Feb 2022
- Funding Round — $77.1M — Nov 2020
Recent signals
- Sep 23, 2025: Raised $59.1M
- Dec 16, 2024: Dewpoint and ConcertAI announce first phase of translational oncology partnership
- Dec 04, 2024: Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Collaborate to Advance Small Molecule Condensate Modulator for ALS
- Feb 04, 2022: Raised $150.0M
- Feb 03, 2022: Raised $150.0M in Series series c
- Nov 02, 2020: Raised $77.1M
See plans & pricing → Track Dewpoint Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.